Hypertension—which occurs in up to 2–3% of expectant mothers—poses a more common dilemma. Unfortunately, exposure to angiotensin-converting enzyme (ACE) inhibitors during the first trimester can increase the risk of cardiovascular and central nervous system anomalies in the neonate. Exposure during the third trimester can cause, inter alia, oligohydramnios, renal dysplasia, anuria and kidney failure. In a recent study, infants exposed to beta-blockers during the third trimester in utero were more than three times more likely to develop hypoglycaemia (relative risk [RR] 3.1) and almost twice as likely to exhibit feeding problems (RR 1.8). Infants exposed to calcium-channel blockers in the third trimester were at an almost four-fold increased risk (RR 3.6) of experiencing seizures (Davis et al, 2010).